Kensey Nash Predicts FDA Will Approve TriActiv In Next 30 Days
This article was originally published in The Gray Sheet
Executive Summary
U.S. clearance of Kensey Nash's TriActiv embolic protection system will not be affected by the fact that FDA has not yet approved drug-eluting stents for treating saphenous vein grafts